2500 — Venus MedTech HangZhou Share Price
0.000.00%
Last trade - 00:00- HK$1.16bn
- HK$1.23bn
- CNY470.83m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.55 | ||
| Price to Tang. Book | 1.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.93% | ||
| Return on Equity | -27.84% | ||
| Operating Margin | -152.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 276.05 | 415.86 | 406.46 | 491.37 | 470.83 | 747.49 | 817.44 | 15.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Venus Medtech Hangzhou Inc is a China-based company principally engaged in the research and development, and the manufacture and sale of bioprosthetic heart valves. The Company mainly engages in minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company provides interventional heart valve devices for valvular heart disease including aortic valve, pulmonic valve, mitral valve and tricuspid valve, a radio frequency ablation system for interventional treatment of HCM, a renal artery denervation ultrasound ablation system for interventional treatment of hypertension and other accessory consumables. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8/TAV8 and TriGUARD3 Cerebral Embolic Protection Device. The Company mainly conducts its businesses in the domestic market and overseas markets.
Directors
- Min Frank Zeng CHM (58)
- Wing-Yu Leung NVC (51)
- Haiyue Ma CFO (43)
- Hou-Sen Lim COO (48)
- Zhenjun Zi GMG (51)
- Christopher Lee Richardson OTH (61)
- Wai Chiu Wong SEC
- Wan Yee Lau NID (74)
- Chi Wai Suen NID (57)
- Ting Yuk Wu NID (67)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 3rd, 2009
- Public Since
- December 10th, 2019
- No. of Employees
- 691
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 441,011,443
- Address
- Room 311, 3/F, Block 2, No. 88, HANGZHOU
- Web
- https://www.venusmedtech.com/
- Phone
- Auditors
- ZHONGHUI ANDA CPA Limited
Upcoming Events for 2500
Half Year 2025 Venus Medtech Hangzhou Inc Earnings Release
Similar to 2500
Acotec Scientific Holdings
Stock Exchange of Hong Kong Limited
Beijing Airdoc Technology Co
Stock Exchange of Hong Kong Limited
AK Medical Holdings
Stock Exchange of Hong Kong Limited
AMCO United Holding
Stock Exchange of Hong Kong Limited
Angelalign Technology
Stock Exchange of Hong Kong Limited
FAQ
What is the Venus MedTech HangZhou share price?
As of Today at 23:57 UTC, shares in Venus MedTech HangZhou are trading at HK$2.92. This share price information is delayed by 15 minutes.
How has the Venus MedTech HangZhou share price performed this year?
Shares in Venus MedTech HangZhou last closed at HK$2.92 and the price had moved by -48.04% over the past 365 days. In terms of relative price strength the Venus MedTech HangZhou share price has underperformed the FTSE Developed Asia Pacific Index by -47.45% over the past year.
What are the analyst and broker recommendations for Venus MedTech HangZhou?
The overall consensus recommendation for Venus MedTech HangZhou is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Venus MedTech HangZhou dividend yield?
Venus MedTech HangZhou does not currently pay a dividend.
Does Venus MedTech HangZhou pay a dividend?
Venus MedTech HangZhou does not currently pay a dividend.
When does Venus MedTech HangZhou next pay dividends?
Venus MedTech HangZhou does not currently pay a dividend.
How do I buy Venus MedTech HangZhou shares?
To buy shares in Venus MedTech HangZhou you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Venus MedTech HangZhou?
As of the previous close price of HK$2.92, shares in Venus MedTech HangZhou had a market capitalisation of HK$1.16bn.
Where are Venus MedTech HangZhou shares listed?
Here are the trading details for Venus MedTech HangZhou:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2500
What kind of share is Venus MedTech HangZhou?
Based on an overall assessment of its quality, value and momentum Venus MedTech HangZhou is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Venus MedTech HangZhou share price forecast for 2025?
The analyst consensus target price for shares in Venus MedTech HangZhou is HK$11.64. That is 298.68% above the last closing price of HK$2.92.
Analysts covering Venus MedTech HangZhou currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.67 for the next financial year.
Find out moreWhat is the trend in the Venus MedTech HangZhou share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Venus MedTech HangZhou. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -44.94%.
As of the last closing price of HK$2.92, shares in Venus MedTech HangZhou were trading -43.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Venus MedTech HangZhou PE Ratio?
The Venus MedTech HangZhou PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$2.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Venus MedTech HangZhou?
Venus MedTech HangZhou's management team is headed by:
- Min Frank Zeng - CHM
- Wing-Yu Leung - NVC
- Haiyue Ma - CFO
- Hou-Sen Lim - COO
- Zhenjun Zi - GMG
- Christopher Lee Richardson - OTH
- Wai Chiu Wong - SEC
- Wan Yee Lau - NID
- Chi Wai Suen - NID
- Ting Yuk Wu - NID